Table 3.
GM of maximum antibody secreting cell (ASC) responses in WRSs2 and WRSs3-immunized subjects.
| Vaccine and vaccine dose (cfu) | IgA |
IgG |
|||||
|---|---|---|---|---|---|---|---|
| LPS | Invaplex | IpaB | LPS | Invaplex | IpaB | ||
|
| |||||||
| 103 | WRSs2 | 5.4 ± 15.4 (50) | 35.2 ± 21.7 (63) | 2.9 ± 8.2 (38) | 2.4 ± 8.9 (13) | 11.5 ± 13.0 (50) | 4.5 ± 10.4 (25) |
| WRSs3 | 2.2 ± 6.8 (13) | 21.3 ± 13.9 (63) | 2.4 ± 7.6 (25) | 2.2 ± 5.0 (13) | 11.9 ± 15.1 (50) | 2.6 ± 14.0 (25) | |
| 104 | WRSs2 | 2.1 ± 5.3 (13) | 6.8 ± 9.5 (38) | 1.3 ± 2.3 (0) | 1.6 ± 3.0 (0) | 5.1 ± 3.9 (38) | 1.5 ± 2.7 (0) |
| WRSs3 | 5.7 ± 8.7 (50) | 19.6 ± 12.3 (50) | 1.9 ± 5.2 (13) | 1.3 ± 3.2 (13) | 8.6 ± 7.8 (38) | 1.7 ± 5.6 (13) | |
| 105 | WRSs2 | 28.7 ± 7.4 (75) | 101.2 ± 4.9 (88) | 12.0 ± 2.7 (75) | 13.1 ± 13.9 (63) | 77.6 ± 5.1 (88) | 16.9 ± 6.5 (50) |
| WRSs3 | 8.2 ± 8.3 (50) | 21.2 ± 16.0 (50) | 4.0 ± 4.7 (25) | 1.8 ± 5.7 (25) | 13.6 ± 5.5 (50) | 4.9 ± 3.9 (25) | |
| 106 | WRSs2 | 63.5 ± 5.2 (88) | 256.6 ± 5.6 (88) | 30.8 ± 14.1 (63) | 22.5 ± 7.5 (75) | 284.0 ± 10.3 (88) | 90.8 ± 31.2 (75) |
| WRSs3 | 9.5 ± 6.2 (50) | 69.8 ± 8.4 (75) | 16.1 ± 11.2 (50) | 5.0 ± 4.7 (38) | 48.2 ± 15.5 (63) | 37.4 ± 27.8 (63) | |
| 107 | WRSs2 | 43.6 ± 4.2 (88) | 151.0 ± 3.3 (1 0 0) | 50.4 ± 6.0 (75) | 11.8 ± 6.8 (50) | 182.0 ± 3.7 (1 0 0) | 119.2 ± 8.2 (88) |
| WRSs3 | 19.8 ± 3.1 (75) | 171.6 ± 3.2 (1 0 0) | 26.9 ± 7.1 (75) | 10.2 ± 6.1 (50) | 98.9 ± 4.9 (88) | 25.1 ± 25.4 (50) | |
| Placebo | 1.0 ± 2.6(0) | 1.0 ± 2.0(0) | 0.9 ± 2.4 (0) | 1.0 ± 2.2 (0) | 1.4 ± 2.5 (0) | 0.7 ± 1.4(0) | |
Geometric Mean ± Standard Deviation, numbers in the parentheses are percent with ≥10 ASC/106 PBMCs.